Skip to main content
POLYMED · Health Care · 2026-08-07

Poly Medicure Ltd

Stage 1 · wk 13In scan: Breakout WatchMARKET: BULL TOPPING · 2026-08-07
₹1,693.8
-0.91% today
₹17,189 Cr · Mid cap
About this companyHealth Care· Health Care Equipment & Supplies
Expand ▾

Poly Medicure Limited engages in the manufacture and sale of medical devices in India and internationally. The company offers infusion therapy products, such as I.V Infusion set, extension lines, needle free connector, I.V flow regulator extension set, burette set, three way stop cock, vial access spike, transfer spike, orburator, polyflush, maifolds, polyswab, and arterial blood collection; critical care products, including vial access spikes, arterial cannula, mini mid lines over the wire, extension line, enteral connector, central venous catheters, and huber needle; dialysis and renal care products, comprising peritoneal dialysis set, haemocent, standard and safety fistula needle, dialyzer, bloodlines and dialysis system. It also provides cardiology products PTFE wire, inflation device, Y-connector, manifold, introducer, IV Cannula, hydrophilic wire, guiding catheter, drug eluting stent, PTCA dilation catheter, diagnostic catheter, and electrocardiograph electrodes; vaccular access products; oncology products; diagnostics products, such as blood collection tubes, safety blood collection set, blood collection needles, and standard needle holder. In addition, the company offers transfusion system products, including blood bags, blood administration set, and others; anesthesia and respiratory care products, comprising variable concentration masks, oxygen mask with reservoirs, fixed concentration masks, aerosol therapy masks, ventilator circuits, suction catheters, spinal needle, polyciser, oxygen catheter, nebulizer compressor system, twin bore nasal oxygen cannula mucus extractor, HME filter, oro-pharyngeal airways, endotracheal tubes, catheter mount, and brain circuit; urology products, including urine collection bags, leg bag set, irrigation sets, foley balloon and urine drainage catheters, and urine collection bags with measured volume meters; wound drainage; and gastroenterology products. The company was incorporated in 1995 and is based in New Delhi, India.

Visit company website →
P/E (TTM)
41.8
Forward 27.3
Earnings Growth (YoY)
-17.6%
Revenue +16.4%
Dividend Yield
0.22%
P/B 4.6
vs 52W High
-20.0%
₹1,191.1 lo₹2,118.1 hi
20.0% below 52W high — deeper pullback
Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.
Stage Maturity
Week 13
1w13w26w
Week 13 — base building
How long this stock has been basing. Longer bases can produce stronger breakouts — but don't anticipate, wait for the breakout.
vs 200 DMA
5.2%
200 DMA: ₹1,610 · sloping down
Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.
Rel Volume
1.50x
vs 50-day avg
Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.
Trend Health
MA20 gently rising · +0.7% vs MA50 +3.7%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
51.6%
20d Δ
+1.6pp
1M return
+3.1%
3M return
+11.6%
Sector Stage-2 % · last 20 days
Sector has 79 Stage 2 leaders. See Health Care Stage 2 →
Industry
Health Care Equipment & Supplies
→ Flat
Stage 2%
37.5%
20d Δ
+0.0pp
1M return
-2.4%
3M return
+3.7%
Industry Stage-2 % · last 20 days
Industry has 3 Stage 2 leaders. See Health Care Equipment & Supplies Stage 2 →
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2023-05-15 → 2026-08-07
S2 26w
S2 46w
S4 44w
2023-05-152026-08-07
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 26w → S3 1w → S2 13w → S3 2w → S2 46w → S3 8w → S4 7w → S1 8w → S4 44w → S1 13w current
Total tracked: 168 weeks across 10 stage runs.
1M
+2.9%
3M
+2.5%
6M
+16.8%
YTD
-2.7%
1Y
-15.1%
Scan Membership
Breakout Watch
Latest: 2024-03-05
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-07S1
Wk 13 · Vol x
2026-08-06S1
Wk 13 · Vol x
2026-08-05S1
Wk 13 · Vol x
2026-08-04S1
Wk 13 · Vol x
2026-08-03S1
Wk 13 · Vol x
2026-07-31S1
Wk 12 · Vol x
2026-07-30S1
Wk 12 · Vol x
2026-07-29S1
Wk 12 · Vol x
2026-07-28S1
Wk 12 · Vol x
2026-07-27S1
Wk 12 · Vol x
2026-07-24S1
Wk 11 · Vol x
2026-07-23S1
Wk 11 · Vol x
Sector Peers — Stage 2All →
DIVISLAB
wk 12 · -3.6% from hi
8.5
LAURUSLABS
wk 16 · -0.3% from hi
8.4
PPLPHARMA
wk 4 · 0.0% from hi
8.2
LALPATHLAB
wk 9 · 0.0% from hi
7.9
SHILPAMED
wk 13 · 0.0% from hi
7.8
Moving averages & range
50 DMA
₹1,604.5
200 DMA
₹1,610
52W High
₹2,118.1
52W Low
₹1,191.1
5D Low
₹1,693.8
Resistance levels (recent highs)
20d High
₹1,727.9
60d High
₹1,732.3
120d High
₹1,732.3
250d High
₹2,118.1
Next resistance
+2.0%
to 20d High

All analytics based on EOD data. Data as of 2026-08-07. Past data patterns are not indicative of future results. This page is a data analytics tool only.